The analysis use paraffin embedded samples and is due to commence in the coming weeks. Tissue samples will become analysed using the Breast Cancer DSA research tool. An Almac bioinformatics group shall interrogate the resulting data to recognize any potential signature. ‘Our research will use the Breast Cancer DSA microarray to examine the transcriptome of ductal carcinoma in situ at a greater level of specificity generating additional information that will assist us pull meaningful conclusions from our data. Eventually we desire to create a gene expression signature that will inform clinical treatment strategies’ said Prof Adrian Harris, Cancer Analysis UK Professor of Medical Oncology at the University of Oxford and Principal Investigator on the study.Patient 2, a 26-year-outdated primigravida, was admitted to the emergency department when she was 9 weeks pregnant, in 2013, with profound hypokalemia and hypomagnesemia . Her hubby had returned from function to find her struggling to operate. She reported fatigue, muscle mass cramps, polyuria, and polydipsia. Her blood circulation pressure was 140/86 mm Hg, and she had a suppressed plasma renin level in the current presence of marked hyperaldosteronism . Her pregnancy was terminated at 10 weeks for personal reasons, and her blood pressure after termination was 110/66 mm Hg.